Leaders in psychedelic
drug development
Since 2017, Ceruvia Lifesciences, founded by Carey Turnbull, has focused on the discovery, development, and commercialization of transformational medicines to deliver meaningful relief to patients suffering from psychiatric and neurological disorders. Leveraging the expertise of some of the world’s leading medical schools, combined with a team of highly experienced drug development professionals, our clinical drug development program is creating new transformational medical breakthroughs.
Carey Turnbull
Founder & CEO
OUR FOUNDER
Carey Turnbull has over a decade of experience in early-stage drug development on behalf of half a dozen companies variously as an investor, founder, and CEO. Early philanthropic donors supporting psychedelic science and research, Carey and Claudia Turnbull have been deeply involved in the development of better treatment options for those suffering from psychiatric and neurological disorders.
In addition to his roles as Founder and CEO of B. More, Ceruvia Lifesciences and Freedom to Operate, Carey is the chair of the advisory board to NYU’s Center for Psychedelic Medicine and a board member of the Heffter Research Institute.
BOARD OF DIRECTORS
Stephen Hurst
David Steinberg
CONTACT CERUVIA
Stay informed of Ceruvia news and research